Lumateperone (Caplyta) for Schizophrenia

Date: July 27, 2020 Issue #:  1603Summary:  The FDA has approved lumateperone (Caplyta— Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Abilify Abilify MyCite Antipsychotics Aripiprazole Asenapine brexpiprazole Caplyta cariprazine Clozapine Clozaril Geodon iloperadine Invega Latuda lumateperone lurasidone Olanzapine paliperidone Quetiapine Rexulti R Source Type: research